Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Individualized Treatment for Non-Small Cell Lung Cancer

November 15th 2013

Drug research and development continues to focus on regimens that select therapy according to the pathologic and molecular characteristics of the tumor.

Dr. Muggia on Targeted Therapies in Ovarian Cancer

November 14th 2013

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

Targeted Therapies Explored in Small Cell Lung Cancer

November 11th 2013

While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.

Dr. Hamid Discusses Melanoma Treatment

October 28th 2013

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses the treatment of melanoma.

Side Effect Management With Corticosteroids

October 27th 2013

The Role of Patient Education in Side Effect Management

October 27th 2013

Managing BRAF Inhibitor Associated Skin Toxicity

October 27th 2013

The Nurse's Role in Managing Skin Toxicity

October 27th 2013

Managing mTOR Inhibitor Induced Adverse Events

October 27th 2013

Interdisciplinary Approach to Managing Skin Toxicities

October 27th 2013

Managing Treatment-Related Hand-Foot Skin Reaction

October 27th 2013

Managing BCR-ABL Inhibitor Associated Skin Rash

October 27th 2013

Managing Angiogenesis Inhibitor Related Skin Toxicity

October 27th 2013

Anticipatory Coping in Patients Treated With EGFR Inhibitors

October 27th 2013

Managing EGFR Inhibitor Associated Skin Toxicity

October 27th 2013

Dr. Tabernero on New Characterizations in CRC

October 18th 2013

Josep Tabernero, MD, PhD, of Vall d'Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

Impact of Molecular Testing on First-Line Treatment Decisions in NSCLC

October 18th 2013

Five lung cancer experts discuss recent advances and current issues surrounding the treatment of non-small cell lung cancer

Expanding TKI Therapy in Advanced Lung Cancer

October 9th 2013

Amid rapid progress in the treatment of advanced lung cancer, several leading organizations have joined in developing new guidelines for the optimal use of molecular testing to help select patients for therapy with tyrosine kinase inhibitors

Dr. Camidge on AP26113 in Advanced Malignancies

October 7th 2013

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.

Dr. Carbone on Potential Biomarkers in Lung Cancer

October 3rd 2013

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.